ReviewPubMed ID: 16107869·2006

Melanocortin-based therapeutics for erection and libido dysfunction

Hadley ME, Dorr RT.

International Journal of Impotence Research, 2006

Key finding

PT-141 demonstrated penile erection in men and increased sexual desire in women through central MC4R activation — a fundamentally novel mechanism distinct from all prior sexual health drugs.

Summary

Review tracing the discovery pathway from melanotan II tanning trials through the serendipitous observation of sexual effects to focused PT-141 development for both male and female sexual dysfunction.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compounds

PT-141L5

An FDA-approved melanocortin receptor agonist used for hypoactive sexual desire disorder in premenopausal women.

Melanotan IIL3

A melanocortin receptor agonist that stimulates melanin production (tanning) and has sexual function effects. Significant safety concerns.

More research on PT-141

Comparison of PT-141 and Flibanserin for Female Sexual Desire Disorder: An Indirect Treatment Comparison

Sexual Medicine Reviews · 2022 · Review

Blood Pressure and Cardiovascular Effects of Bremelanotide in Hypertensive Versus Normotensive Women

Journal of Sexual Medicine · 2021 · Human RCT

Long-Term Safety and Efficacy of Bremelanotide: 1-Year Extension Study in Women with HSDD

The Journal of Sexual Medicine · 2021 · Human Pilot

RECONNECT-1: A Randomized Controlled Trial of Bremelanotide for Female Sexual Desire Disorder

The Journal of Sexual Medicine · 2020 · Human RCT

RECONNECT-2: Phase 3 Trial of Bremelanotide in Premenopausal Women with Generalized Hypoactive Sexual Desire Disorder

The Journal of Sexual Medicine · 2020 · Human RCT